- Home
- ARL vs DSGN Comparison
ARL vs DSGN Comparison
Compare ARL & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARL
- DSGN
- Stock Information
- Founded
- ARL 1999
- DSGN 2017
- Country
- ARL United States
- DSGN United States
- Employees
- ARL N/A
- DSGN N/A
- Industry
- ARL Building operators
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- ARL Real Estate
- DSGN Health Care
- Exchange
- ARL Nasdaq
- DSGN Nasdaq
- Market Cap
- ARL 245.7M
- DSGN 208.9M
- IPO Year
- ARL N/A
- DSGN 2021
- Fundamental
- Price
- ARL $16.01
- DSGN $6.24
- Analyst Decision
- ARL
- DSGN
- Analyst Count
- ARL 0
- DSGN 0
- Target Price
- ARL N/A
- DSGN N/A
- AVG Volume (30 Days)
- ARL 1.1K
- DSGN 196.1K
- Earning Date
- ARL 11-07-2025
- DSGN 11-07-2025
- Dividend Yield
- ARL N/A
- DSGN N/A
- EPS Growth
- ARL N/A
- DSGN N/A
- EPS
- ARL N/A
- DSGN N/A
- Revenue
- ARL $48,139,000.00
- DSGN N/A
- Revenue This Year
- ARL N/A
- DSGN N/A
- Revenue Next Year
- ARL N/A
- DSGN N/A
- P/E Ratio
- ARL N/A
- DSGN N/A
- Revenue Growth
- ARL N/A
- DSGN N/A
- 52 Week Low
- ARL $9.43
- DSGN $2.60
- 52 Week High
- ARL $18.00
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- ARL 53.74
- DSGN 49.22
- Support Level
- ARL $15.61
- DSGN $6.25
- Resistance Level
- ARL $16.89
- DSGN $6.77
- Average True Range (ATR)
- ARL 0.24
- DSGN 0.48
- MACD
- ARL 0.02
- DSGN 0.02
- Stochastic Oscillator
- ARL 51.64
- DSGN 49.74
About ARL American Realty Investors Inc.
American Realty Investors Inc is a fully integrated externally managed real estate company. The company operates high-quality multifamily and commercial properties throughout the Southern United States and also invests in mortgage notes receivable and in land that is either held for appreciation or development. It operates in two reportable segments; the acquisition, development, ownership and management of multifamily properties (Residential); and the acquisition, development, ownership, and management of commercial properties (Commercial), which predominantly comprise office properties. Maximum revenue is generated from its Residential segment, which includes the rental of apartments and other tenants.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.